Bupropion for Smoking Cessation
Bupropion is highly effective for smoking cessation and should be initiated 1-2 weeks before the quit date at 150 mg once daily for 3 days, then increased to 150 mg twice daily (maximum 300 mg/day) for 7-12 weeks. 1
Dosing Protocol
Start bupropion 1-2 weeks before the target quit date to allow therapeutic levels to build up before nicotine withdrawal begins 1:
- Days 1-3: 150 mg orally once daily
- Day 4 through week 12: 150 mg orally twice daily (if tolerated)
- Maximum dose: 300 mg per day
- Duration: 7-12 weeks initially, though therapy may be extended to 6 months-1 year to promote continued cessation 1
Efficacy
Bupropion substantially improves smoking cessation rates. High-certainty evidence demonstrates that bupropion increases long-term quit rates (RR 1.64,95% CI 1.52-1.77) 2. Meta-analyses show it improves 12-month sustained abstinence rates and reduces withdrawal symptom severity 3. The drug's efficacy appears independent of its antidepressant effects and works through dopamine and norepinephrine reuptake inhibition 3, 4.
Combination Therapy
Bupropion can be combined with nicotine replacement therapy (NRT), though evidence for superior efficacy is mixed 1. The NCCN guidelines list "Bupropion ± NRT" as a preferred primary therapy option 1. However, when combining bupropion with NRT patches, monitor blood pressure more closely as hypertension rates may increase (6.1% with combination vs 2.5% with bupropion alone) 5.
Bupropion is less effective than varenicline (RR 0.71,95% CI 0.64-0.79), but appears equivalent to NRT alone 2.
Critical Contraindications
Bupropion is absolutely contraindicated in patients with:
- Seizure disorder or conditions increasing seizure risk (stroke, brain metastases, severe head injury, arteriovenous malformation, CNS tumor/infection, anorexia nervosa, bulimia) 1, 5
- Current MAO inhibitor use (increased hypertensive reaction risk) 1
- Concurrent tamoxifen use 1
- Closed-angle glaucoma 1
The seizure risk with bupropion is approximately 0.1% (1 in 1,000) at recommended doses 3, 5. This risk increases nearly tenfold at doses above 450 mg/day 5.
Safety Monitoring
Monitor for neuropsychiatric adverse events, though recent high-quality evidence is reassuring. A large multicenter RCT (EAGLES trial) with over 8,000 patients found that neuropsychiatric adverse event rates with bupropion were not significantly increased compared to nicotine patches or placebo, even in patients with pre-existing psychiatric disorders 1.
Despite this reassuring data, the FDA maintains warnings about potential mood changes, depression, mania, psychosis, suicidal ideation, and aggressive behavior 5. Advise patients to immediately report agitation, depressed mood, behavioral changes, or suicidal thoughts 5.
Monitor blood pressure periodically during treatment, as bupropion can cause hypertension 5. This is particularly important in patients with pre-existing hypertension or cardiovascular disease.
Common Side Effects
The most frequent adverse effects are 1, 6:
- Insomnia (most common, often transient)
- Dry mouth
- Headache
- Nausea
- Anxiety (also a nicotine withdrawal symptom)
High-certainty evidence shows bupropion increases treatment discontinuation due to adverse events (RR 1.37,95% CI 1.21-1.56) compared to placebo 2. However, most side effects are mild, transient, and can be managed by dose reduction if needed 6.
Special Populations
For patients with depression or psychiatric history: Bupropion remains effective and safe based on the EAGLES trial data 1. However, conduct a suicide risk assessment before prescribing 7.
For patients with cardiovascular disease: Bupropion has been studied in this population and appears safe when used appropriately 7, 4. Monitor blood pressure closely.
For patients with COPD: Evidence supports bupropion's efficacy and safety in this population 8.
Clinical Pearls
- Inadequate NRT dosing is a common cause of cessation failure 4. When combining therapies, ensure adequate nicotine replacement.
- Behavioral support enhances outcomes. All pharmacotherapy should be combined with counseling 9.
- If initial treatment fails, patients may continue, resume, or switch to alternative pharmacotherapy (varenicline or combination NRT) 1.
- Weight gain concerns: Bupropion attenuates post-cessation weight gain (average 5 kg expected), though the health benefits of cessation far outweigh weight gain risks 7, 10.
- Re-treatment is effective in patients who resume smoking after a previous bupropion course 10.